Cloning & Mutagenesis Market to Grow with a CAGR of 18.99% through 2030
Increasing prevalence of chronic and genetic diseases is
expected to drive the growth of global cloning & mutagenesis in the
forecast period, 2026-2030.
According to TechSci Research report, “Cloning &
Mutagenesis Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2030F”, the Global Cloning & Mutagenesis Market was valued at
USD 2.67 Billion in 2024 and is expected to reach USD 7.58 Billion by 2030 with
a CAGR of 18.99%. This can be ascribed to the increasing prevalence of chronic
and genetic diseases like cancer and HIV, along with growing healthcare
expenditure across the globe. Additionally, growing investment on research and
development for the treatment of genetic disorders and other diseases,
especially in the developed countries in the North America and Europe, is expected
to create lucrative opportunities for the market growth in the coming years.
Besides, increasing demand for laboratory automation and more awareness of
preventive healthcare is further expected to support the market growth.
Similarly, the increasing demand for personalized medicine adoption of cloning
and mutagenesis tools have increased such as PCR is expected to boost the
market growth during the forecasted period. Also, the growing focuses on
protein engineering for drug development is expected to drive the growth of the
market. Additionally, growing demand for genetically modified products such as
crops is anticipated to drive the growth of the market over the years.
However, high cost of cloning and mutagenesis kits can
create affordability issues thereby slowing down the growth of global cloning
& mutagenesis market in the forecast period. Similarly, high risks and
complications associated with treatments, may hamper the cloning &
mutagenesis market growth during the forecast period. Also, lack of accuracy in
methods of cloning and mutagenesis, along with ethical issues surrounding the
terminology in emerging countries, can further restrict the growth of global
cloning & mutagenesis market. Also, lack of infrastructure and instruments
may hamper the growth of the market during the forecasted years.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Cloning & Mutagenesis Market"
The Global Cloning & Mutagenesis Market is
segmented into gene type, product type, technique, application, end user,
regional distribution, company.
Based on Product Type, Mutagenesis kits are experiencing the
fastest growth in the global cloning and mutagenesis market, largely fueled by
their increasing importance in functional genomics, protein engineering, drug
discovery, and cancer research. These kits are designed to introduce specific
mutations into DNA sequences, enabling researchers to study gene function,
protein structure, and the effects of genetic alterations. Their growing use in
both basic research and applied biotechnology is a major driver of their rapid
adoption across the globe. One of the key factors propelling the growth of
mutagenesis kits is the surge in precision medicine initiatives and targeted
therapeutic development. Site-directed mutagenesis has become a cornerstone of
efforts to identify gene variants responsible for diseases and to develop
targeted gene therapies. The U.S. National Cancer Institute (NCI) continues to
fund large-scale genomic projects, including The Cancer Genome Atlas (TCGA) and
the Cancer Moonshot initiative, which rely heavily on mutation analysis to
guide therapeutic innovation. As per the NIH budget data for FY 2023, over $1.5
billion was allocated to cancer genetics and precision medicine—fields where
mutagenesis kits play a pivotal role.
Based on the Region, The Asia-Pacific region is experiencing
the fastest growth in the global cloning and mutagenesis market, driven by
increasing investments in biotechnology research, expanding healthcare
infrastructure, and growing demand for genetically modified crops and targeted
therapeutics. Several governments across the region are actively promoting
genomics and molecular biology as part of national development strategies,
making Asia-Pacific a dynamic hotspot for genetic engineering advancements. One
of the most significant growth drivers in Asia-Pacific is China’s commitment to
biotechnology innovation. The Chinese government has made biotechnology a
strategic priority under its 14th Five-Year Plan (2021–2025), with the Ministry
of Science and Technology designating genomics and synthetic biology as key
areas of development. According to the China National Center for Biotechnology
Development, the country invested over $12 billion in biotechnology R&D in
2023, much of which was directed toward gene editing, cloning, and crop
improvement technologies. India is another critical growth engine in the
region. Under the Department of Biotechnology (DBT) and ICAR (Indian Council of
Agricultural Research), India has made significant strides in crop genomics and
mutagenesis research. Programs like the Biotechnology Industry Research
Assistance Council (BIRAC) have funded numerous start-ups and academic
institutions to develop gene-cloning platforms and novel mutagenesis
techniques. As per the DBT’s 2023–24 report, the government allocated INR 2,400
crore (~$290 million USD) specifically for biotechnology research and
innovation, which includes gene-editing and functional genomics tools.
Major companies operating in Global Cloning &
Mutagenesis Market are:
- Agilent
Technologies, Inc.
- Eurofins
Scientific SE
- Sartorius
AG
- Collecta,
Inc.
- Codex
DNA Inc.
- Lonza
Group AG
- Charles
River Laboratories International, Inc.
- TransGene
Biotech Co. Ltd.
- Takara
Bio, Inc.
- Thermo
Fisher Scientific Inc.
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“The North America was expected to dominate in the
global cloning & mutagenesis market on account of
increasing investment by government organizations for the development of stem
cell and cancer research across the region. Furthermore, increasing number of
biotechnology companies in the region, along with increasing prevalence of chronic
diseases, are further contributing to the demand for cloning and mutagenesis
market. Besides, increasing demand for adopting personalized medicine services
and developing healthcare systems for the treatment of different type of
chronic diseases like breast cancer, prostate cancer, blood cancer in the
region, are further expected to create lucrative opportunities for the market
growth” said Mr. Karan Chechi, Research Director of TechSci Research, a
research based global management consulting firm.
“Cloning & Mutagenesis Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, Segmented By Gene Type
(Standard, Complex), By Product Type (Cloning Kits, Mutagenesis Kits), By
Technique (Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed
Mutagenesis, Others), By Application (Gene Synthesis, Gene Expression, Gene
Therapy, Vaccine Research, Others), By End User (Pharmaceutical &
Biotechnology Companies, Academic & Research Institutions, Others), By
Region and Competition, 2020-2030F”, has evaluated the future growth
potential of global cloning & mutagenesis market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in global cloning & mutagenesis market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com